SIDE EFFECTS

The following additional adverse reactions have been
identified during post-approval use of HUMULIN N. Because these reactions are
reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or to establish a causal
relationship to drug exposure.

Allergic Reactions

Some patients taking HUMULIN N have experienced erythema,
local edema, and pruritus at the site of injection. These conditions were
usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have
been reported [see WARNINGS AND PRECAUTIONS].

Peripheral Edema

Some patients taking HUMULIN N have experienced sodium
retention and edema, particularly if previously poor metabolic control is
improved by intensified insulin therapy.

Lipodystrophy

Administration of insulin subcutaneously, including
HUMULIN N, has resulted in lipoatrophy (depression in the skin) or
lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND
ADMINISTRATION] in some patients.

Weight gain

Weight gain has occurred with
some insulin therapies including HUMULIN N and has been attributed to the
anabolic effects of insulin and the decrease in glycosuria.

Immunogenicity

Development of antibodies that react with human insulin
have been observed with all insulin, including HUMULIN N.

Drugs That May Increase Or Decrease The Blood Glucose
Lowering Effect Of HUMULIN N

The glucose lowering effect of HUMULIN N may be increased
or decreased when co-administered with beta-blockers, clonidine, lithium salts,
and alcohol. Pentamidine may cause hypoglycemia, which may sometimes be
followed by hyperglycemia. Dose adjustment and increased frequency of
glucose monitoring may be required when HUMULIN N is co-administered with these
drugs.

Drugs That May Blunt Signs And Symptoms Of Hypoglycemia

The signs and symptoms of hypoglycemia [see WARNINGS
AND PRECAUTIONS] may be blunted when beta-blockers, clonidine,
guanethidine, and reserpine are co-administered with HUMULIN N.